Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Narrative (Details)

v3.10.0.1
Revenue Recognition - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]    
Increase in pharma contract liabilities $ 900  
Increase in pharma contract liabilities (as a percent) 53.00%  
Capitalized contract costs $ 921 $ 542
Pharma contract liability, revenue recognized 1,600  
Amortization of contract commissions 1,000  
Sales Commissions    
Disaggregation of Revenue [Line Items]    
Capitalized contract costs $ 400  
Capitalized contract costs (as a percent) 70.00%